Rapid suppression of myeloid infiltration during acute colitis effectively controls inflammation.[51] However, systemic anti‐TNF therapies struggle to sustain efficacy due to their short half‐lives and poor accumulation at the site of inflammation.[52, 53] Enhanced colonization of EcNΔlpp::A5‐aTN enables prolonged nanobody release during mucosal repair, allowing long‐term immune modulation. Here, TNF is linked to colitis.